The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health

Part of paid clinical trials in Tampa, Florida.

Sponsor
Applied Science & Performance Institute
Study ID
NCT07760506
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Coenzyme Q10
  • Healthy Aging
  • Inflammaging
  • Metabolic Health
  • Quercetin

Eligibility Criteria

Sex
ALL
Age
50 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • Quercetin (dietary supplement) — DIETARY_SUPPLEMENT
    Natural compound found in foods like apples and onions that may help reduce inflammation and support overall health.
  • Coenzyme Q10 — DIETARY_SUPPLEMENT
    Substance made by the body that helps produce energy in cells and also acts as an antioxidant to support heart and overall health.
  • Rice Flour — DIETARY_SUPPLEMENT
    An inert carbohydrate used as the control treatment

Study Details

The goal of this clinical trial is to learn if Quercefit® or Ubiqsome™ can improve markers of healthy aging, blood sugar control, and heart health in older adults. It will also learn about the safety of these supplements. The main questions it aims to answer are: 1. Do Quercefit® or Ubiqsome™ improve blood sugar, cholesterol, and markers of aging compared to a placebo? 2. What side effects, if any, do participants have while taking these supplements? Researchers will compare Quercefit® (500 mg/day), Ubiqsome™ (300 mg/day), and a placebo (a look-alike capsule with no active ingredient). Participants will: 1. Take their assigned capsules (Quercefit®, Ubiqsome™, or placebo) twice daily for 12 weeks 2. Go to a preferred clinic at the start and end of the study for a fasting blood draw Complete at-home tests: 3. Grip strength testing (using a device mailed to them) 4. Online surveys about fatigue and quality of life 5. Report any side effects and keep track of supplement use

Key Dates

First listed
Aug 12, 2026
Start date
Aug 31, 2026
Status verified
Aug 2026
Primary completion
Aug 31, 2028
Completion
Aug 31, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Group 1 (Quercefit® only)
    500 mg Quercefit® per day, administered as one 250 mg capsule taken twice daily (morning and evening)
  • Active Comparator: Group 2 (Ubiqsome™ only)
    300 mg Ubiqsome™ per day, administered as one 150 mg capsule taken twice daily (morning and evening)
  • Placebo Comparator: Group 3 (Placebo)
    One placebo capsule taken twice daily (morning and evening)

Primary Outcome Measure

Inflammaging (CIMKDM) [ Time Frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The Applied Science and Performance InstituteTampaFlorida33634
Gabe Wilson, PhD
[email protected]
8136738888
Eric Sikorski, PhD
[email protected]
8136738888
Jacob Wilson, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Tampa, FL

By research site
The Applied Science and Performance Institute· Tampa, FL

Related Studies